Enhancing the in vitro and in vivo activity of itraconazole against breast cancer using miltefosine-modified lipid nanocapsules
Itraconazole (ITC), a well-tolerated antifungal drug, exerts multiple anticancer effects which justified its preclinical and clinical investigation as potential anti-cancer agent with reduced side effects. Enhancement of ITC anti-cancer efficacy would bring valuable benefits to patients. We propose...
Main Authors: | Nabila A. El-Sheridy, Riham M. El-Moslemany, Alyaa A. Ramadan, Maged W. Helmy, Labiba K. El-Khordagui |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2021-01-01
|
Series: | Drug Delivery |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/10717544.2021.1917728 |
Similar Items
-
Single oral fixed-dose praziquantel-miltefosine nanocombination for effective control of experimental schistosomiasis mansoni
by: Maha M. Eissa, et al.
Published: (2020-09-01) -
Miltefosine Lipid Nanocapsules for Single Dose Oral Treatment of Schistosomiasis Mansoni: A Preclinical Study.
by: Maha M Eissa, et al.
Published: (2015-01-01) -
Praziquantel–lipid nanocapsules: an oral nanotherapeutic with potential Schistosoma mansoni tegumental targeting
by: Amara RO, et al.
Published: (2018-08-01) -
Cyclosporine Lipid Nanocapsules as Thermoresponsive Gel for Dry Eye Management: Promising Corneal Mucoadhesion, Biodistribution and Preclinical Efficacy in Rabbits
by: Lubna M. Eldesouky, et al.
Published: (2021-03-01) -
EVALUATION OF MILTEFOSINE AGAINST LEISHMANIA MAJOR (MRHO/IR/75/ER): IN VITRO AND IN VIVO STUDIES
by: J. Esmaeili, et al.
Published: (2008-06-01)